retatrutide fda approval status november 2025 Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and June 8, 2026: Reckless physicians

Many women ask if GLP-1s are safe to take postpartum as a way to get back to their pre-pregnancy weight

Eli Lilly narrative, and how this news fits the story These moves line up closely with existing community narratives that focus on GLP-1 capacity constraints, Medicare access, and the need to turn today's blockbuster obesity franchise into a broader, more durable portfolio

Spirulina ( Arthrospira platensis ) used as functional feed supplement or alternative protein source: a review of the effects of different dietary inclusion levels on production performance, health status, and meat quality of broiler chickens

Medicare will cover GLP-1s for a BMI of 35 or more, or a BMI of 27 or more with some qualifying conditions: The prescription must be for weight reduction and weight maintenance in combination with lifestyle modification (structured nutrition and physical activity)

IGF 1 LR3: Supports anabolic processes directly related to GH signaling

Many products are research-grade and may lack consistent quality standards